Xin Lang Cai Jing·2025-11-17 06:27Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on April 21, 1998. The company was listed on May 6, 2010. Its main business involves the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [1] - The company's revenue composition includes: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [1] Financial Performance - As of September 30, 2025, Hepalink achieved operating revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%. However, the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [2] - The company has cumulatively distributed 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [3] Stock Market Activity - On November 17, Hepalink's stock price decreased by 2.07%, trading at 12.30 yuan per share, with a total market capitalization of 18.048 billion yuan. The trading volume was 39.08 million yuan, with a turnover rate of 0.25% [1] - Year-to-date, Hepalink's stock price has increased by 17.82%, with a recent decline of 0.57% over the past five trading days and a 5.22% increase over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 12.0093 million shares, an increase of 691,700 shares compared to the previous period [3]